-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
OG-L002
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1357302-64-7.gif)
| Category | Herpes simplex Virus (HSV) |
| CAS | 1357302-64-7 |
| Description | OG-L002 potently inhibits HSV IE gene expression in both HeLa and HFF cells with IC50s of ~10 μM and ~3 μM, respectively. OG-L002 is a potent and highly selective inhibitor of LSD1 (IC50 = 0.02 μM), and is a potent inhibitor of monoamine oxidases (MAO) with IC50s of 1.38 and 0.72 μM for MAO-A and MAO-B, respectively. |
Product Information
| Synonyms | 4'-[(1R,2S)-2-Aminocyclopropyl]-[1,1'-biphenyl]-3-ol; 4'-((1R,2S)-2-Aminocyclopropyl)biphenyl-3-ol; [1,1'-Biphenyl]-3-ol, 4'-[(1R,2S)-2-aminocyclopropyl]-; 4'-[(1R,2S)-2-Aminocyclopropyl]-3-biphenylol |
| IUPAC Name | 3-[4-[(1R,2S)-2-aminocyclopropyl]phenyl]phenol |
| Molecular Weight | 225.29 |
| Molecular Formula | C15H15NO |
| Canonical SMILES | C1C(C1N)C2=CC=C(C=C2)C3=CC(=CC=C3)O |
| InChI | InChI=1S/C15H15NO/c16-15-9-14(15)11-6-4-10(5-7-11)12-2-1-3-13(17)8-12/h1-8,14-15,17H,9,16H2/t14-,15+/m1/s1 |
| InChIKey | DSOJSZXQRJGBCW-CABCVRRESA-N |
| Boiling Point | 416.7±45.0°C (Predicted) |
| Flash Point | 205.8±28.7 °C |
| Purity | >98% |
| Density | 1.193±0.06 g/cm3 (Predicted) |
| Solubility | Soluble in DMSO, Ethanol |
| Appearance | Off-white Solid |
| Storage | Store at -20°C |
| Complexity | 260 |
| Exact Mass | 225.115364102 |
| Index Of Refraction | 1.644 |
| In Vitro | OG-L002 inhibits viral IE gene expression in both cells with a significantly reduced IC50 (IC50: ~10 µM in HeLa cells; IC50: ~3 µM in HFF cells) relative to the control MAOI TCP (IC50: ~1 mM). |
| In Vivo | OG-L002 (i.p.; 6-40 mg/kg; daily; for 7 days) reduces the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection. Animal Model: 4-week-old BALB/c female mice Dosage: 6, 20, 40 mg/kg Administration: Intraperitoneal; daily; for 7 days Result: Reduced the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection. |
| PSA | 46.25000 |
| Target | IC50: 0.02 μM (LSD1), 1.38 μM (MAO-A), 0.72 μM (MAO-B), HSV IE |
| Vapor Pressure | 0.0±1.0 mmHg at 25°C |
| XLogP3-AA | 2.5 |
